Condition
JMML
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 1 (1)
Trial Status
Recruiting1
Terminated1
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT05849662Phase 1Recruiting
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
NCT00176930Not ApplicableTerminated
Stem Cell Transplant for Hematological Malignancy
NCT04505995Not ApplicableUnknownPrimary
Azacitidine and Homoharringtonine in JMML
Showing all 3 trials